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Abstract: The ambulation-increasing effect of scopolamine (SCP: 2 mg/kg s.c.), a muscarinic anti-cholinergic drug, was 
inhibited by simultaneously administered pilocarpine (PILO: 1, 3 and 10 mg/kg s.c.) in a dose-dependent manner.  The 
behavioral tolerance to SCP induced by repeated administration at 3-day intervals was protected when PILO (10 mg/kg) 
was administered at post-scopolamine period of 0 min (simultaneous) and 5 min, but not 20 min or later, although the 
repeated administrations of PILO alone did not change the sensitivity to SCP.  These treatments induced no significant 
change in the sensitivity to methamphetamine (2 mg/kg s.c.).  These results suggest that repeated experience of both the 
muscarinic anti-cholinergic effect of SCP and the free ambulation during the early post-SCP period of 0-20 min is essential 
factor for the induction of behavioral tolerance to SCP in mice.  It is also suggested that repeated experience of both central 
and peripheral anti-cholinergic effect may not increase the risk to psychotoxic effect of psychomotor stimulants such as 
methamphetamine.
(Reprint request should be sent to Hisashi Kuribara)
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Introduction
Scopolamine (SCP), a muscarinic anti-cholinergic drug, 
blocks both the central and peripheral muscarinic acetyl-
choline receptors.  It has been considered that the blockade 
of the central cholinergic systems (Mathura et al., 1997; 
Shannon and Peters, 2001; Chintoh et al., 2003) and resul-
tant stimulation of the dopaminergic system (Fink and 
Morgenstern, 1980) are involved in the SCP-induced 
hyperactivity.
In contrast to the psychomotor stimulants such as 
amphetamines and cocaine (Kuribara and Hirabayashi, 
1985; Kuribara, 1996, 2009), repeated administration of 
SCP to the mice at intervals of 1 day or longer produced 
a significant tolerance to the ambulation-increasing effect 
(Kuribara and Tadokoro, 1983, 1987).  The induction of 
tolerance to SCP was highly dependent on environmental 
situation (Kuribara, 2011).  The mice repeatedly given 
SCP showed tolerance and no tolerance when they were 
individually put in the wide activity cages and in the 
narrow jars, respectively, during the presence of drug 
effect.  Furthermore, it has been demonstrated that the 
mice pretreated with SCP exhibited neither tolerance 
nor sensitization to the ambulation-increasing effect of 
methamphetamine, a psychomotor stimulant (Fujii et al., 
1990).
The aims of this study were to assess furthermore the 
role of the central and peripheral cholinergic mechanisms 
on the behavioral tolerance to SCP, and the induction of 
psychotoxic symptoms caused by a psychomotor stimu-
lants.  To simultaneously block the central and pheripheral 
muscarinic cholinergic receptors, pilocarpine (PILO) was 
administered at several post-SCP periods.  The sensitivity 
to methamphetamine, a psychomotor stimulant drug was 
also assessed in the mice treated with the combined 
administration of SCP + PILO.
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Materials and Methods
 Animals
Male mice of the ddY strain (SLC Japan, Hamamatsu) 
were purchased at 5 weeks of age, and they were used at 6 
weeks of age; weighing at 25-28 g.  Groups of 10 mice 
each had been housed in Polycarbonate cages (20W × 
25L × 15H cm) with free eating a solid diet (MF: Orien-
tal Yeast, Tokyo) and tap water except during the behav-
ioral tests.  The breeding room was controlled to 
temperature being 23 ± 1 °C, relative humidity being 55 
± 3 %, and a 12:12-hr light-dark cycle; lights (approxi-
mately 500 lx) on between 06:00-18:00 hr.  The environ-
mental conditions, temperature and relative humidity, of 
the experimental room were almost the same as those of 
the breeding room.
All the experimental treatments mentioned below were 
carried out following “The Guiding Principles for the 
Care and Use of Laboratory Animals” of The Japanese 
Pharmacological Society.
Apparatus
The apparatus for measurement of ambulatory activity 
of mice was a tilting-type “ambulometer” (SMA-10: 
O’hara & Co., Tokyo), which was the same as that used in 
the previous studies (Kuribara, 2011, 2012).
Drugs
The drugs used were scopolamine hydrobromide (SCP: 
Sigma Chem., St.  Louis, MO), pilocarpine chloride 
(PILO: Sigma Chem.) and methamphetamine hydrochlo-
ride (MA; Philopon: Dainippon-Sumitomo Pharm., Osaka). 
These drugs were dissolved in physiological saline, and 
subcutaneously (s.c.) administered at a constant volume of 
0.1 ml/10 g body weight of the mouse independent of the 
doses (shown in the salt forms) of drugs.
Experimental schedules
All the experimental treatments; the administration of 
SCP, PILO and MA, and the measurement of ambulatory 
activity of the mice, were carried out between 09:00-
16:00 hr.
In the case of measurement of the activity of mice, they 
were individually put in the activity cages of 20 cm in 
diameter and 12.5 cm in height for 10 min, and then the 
drug administration was conducted.  The activity of each 
mouse was measured for 90 and 180 min after administra-
tions of SCP + PILO and MA, respectively.
1) Repeated administration of SCP + PILO and the 
challenge administration of SCP and MA
Four groups of mice (10 mice each) were given SCP 
(2 mg/kg s.c.) + PILO (0: saline, 1, 3 and 10 mg/kg s.c.) for 
5 times at intervals of 3 days.  As the control administra-
tion, other 4 groups of 10 mice each were given PILO (0, 
1, 3 and 10 mg/kg) alone.  After each drug administration, 
ambulatory activity of mouse was measured for 90 min.
Three days after the final (5th) pre-treatment with SCP 
(2 mg/kg) + PILO (0, 1, 3 and 10 mg/kg) or PILO (0, 1, 3 
and 10 mg/kg) alone, each group of 10 mice was divided 
into two almost equivalent subgroups of 5 mice each.  One 
subgroup was challenge-administered SCP (2 mg/kg s.c.), 
and ambulatory activity was measured for 90 min.  The 
other subgroup was challenge-administered MA (2 mg/kg 
s.c.), and ambulatory activity was measured for 180 min.
Other 2 groups of 5 drug-naïve mice each were adminis-
tered SCP and MAP as the controls.
2) Repeated administration of SCP + post-SCP treat-
ment with PILO, and challenge-administration of SCP and 
MAP
Four groups 10 mice each were administered SCP (2mg/
kg s.c.) 5 times at intervals of 3 days.  Each SCP adminis-
tration was followed by the administration of PILO (10 
mg/kg s.c.) at 0 (simultaneous), 5, 10, 20, 30, 60 or 90 min 
(immediately after the end of measurement of ambulatory 
activity). Ambulatory activity of each mouse was measured 
for 90 min after the SCP administration.
Three days after the final treatment, all groups of mice 
were divided into two almost equivalent subgroups of 5 
mice each, and they were challenge-administered SCP and 
MA, respectively.
Statistical analysis
Mean activity counts in each group for 90 min and 180 
min after the administration of SCP + PILO and MA, 
respectively, were analyzed by one-way analysis of vari-
ance (ANOVA).  Post-hoc analyses were carried out by 
Bonferroni test.  Values of p less than 0.05 were considered 
significant.  
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Results
Repeated SCP + PILO administration and challenge-
administration of MA
As shown in Table 1, PILO reduced ambulation-increasing 
effect of SCP in a dose-dependent manner.  The mice given 
SCP + PILO showed the tolerance following repeated 
administrations.
Repeated administrations of PILO alone caused very 
low activity counts (12-36 counts) throughout five admin-
istrations (data not shown).
As shown in Table 2, the mice pretreated with SCP + PILO 
showed recovery of activity at the challenge-administration of 
SCP dependent on the doses of PILO, although the 
pretreatment with PILO did not change the sensitivity to SCP.
Pretreatments with SCP + PILO or PILO caused no sig-
nificant change in the sensitivity to MA.  
Repeated administration of SCP + post-SCP treatment 
with PILO, and challenge-administration of SCP
As shown in Table 3, repeated administration of SCP + 
post-SCP treatment with PILO at 5, 10, 20, 30, 60 and 90 
min exhibited a progressive decrease in the activity counts. 
The groups of mice received simultaneous administration 
of SCP + PILO demonstrated low activity counts through-
out repeated administration for 5 times.
As shown in Table 4, except the groups of mice received 
repeated administrations of SCP + PILO (simultaneous) 
and SCP + post-SCP treatment with PILO at 5 min, the 
other 6 groups of mice received SCP + post-SCP treat-
ments with PILO at 10, 20, 30, 60 and 90 min showed 
almost the same activity counts as that of the SCP alone 
treated mice.
Pretreatments with SCP + pos-SCP treatment with PILO 
induced no significant change in the sensitivity to MA.  
Table 1.   Mean activity counts of mice following repeated co-administration of scopolamine  
(SCP: 2 mg/kg s.c.) + pilocarpine (PILO: 0, 1, 3 and 10 mg/kg s.c.) for 5 times at 3-day ntervals.
Doses of drugs 1st 2nd 3rd 4th 5th
SCP alone 533±61 202±28* 121±15* 103±15* 96±13*
SCP + PILO (1) 309±52$ 118±31*,$ 86±20* 63±14*,$ 55±11*,$
SCP + PILO (3) 122±33$ 58±12*,$ 48± 9*,$ 41± 7*,$ 36± 5*,$
SCP + PILO (10) 31± 6$ 27± 5$ 23± 4$ 19± 4$ 21± 6$
N=10 in each group.  *: significantly lower (p<0.05) vs. the value at the 1st administration within group.   
$: significantly lower than the value of SCP-treated group at the same administration.
Table 2.   Mean activity counts after challenge-administration of scopolamine  
(SCP: 2 mg/kg s.c.) and methamphetamine (MA: 2 mg/kg s.c.) to the mice 
pretreated with SCP (2 mg/kg s.c.) + pilocarpine (PILO: 0, 1, 3, and 10 
mg/kg s.c.), or PILO alone for 5 times at 3-day intervals.
Pretreatments (5 times)
Challenge-administrations
SCP MA
Saline 572± 93 1765±318
SCP alone 92± 18* 1849±356
SCP + PILO 1 mg/kg 228± 39* 1749±320
SCP + PILO 3 439± 77 1805±353
SCP + PILO 10 603±106 1849±318
PILO 1 mg/kg 594± 95 1829±341
 3 616±109 1749±356
 10 607±101 1894±397
N=5 in each group.  *: p<0.05 vs. the value of saline-pretreated group.   
$: p<0.05 vs. the value of mice pretreated with SCP alone.
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Gross observation
The mice given PILO alone and combination of SCP + 
PILO (10 mg/kg) exhibited parasympathomimetic symp-
toms such as increased salivation and tearing.
Discussion
Repeated administration of SCP alone to the mice at 
intervals of 3 days induced tolerance to the ambulation-
increasing effect.  This result is consistent with the previous 
reports (Kuribara and Tadokoro, 1983, 1987).  The indirect 
stimulation of the central dopaminergic system (Fink and 
Morgenstern, 1980) caused by the blockade of the central 
cholinergic systems (Mathura et al., 1997; Shannon and 
Peters, 2001; Chintoh et al., 2003) are involved in the SCP-
induced hyperactivity.  However, the author reported that 
the induction of tolerance to SCP was highly dependent on 
the environment (Kuribara, 2011).
To evaluate the role of cholinergic system in the tolerance 
to SCP, PILO which had agonistic action on both the central 
and peripheral muscarinic cholinergic receptors drug was 
used in this study.  PILO not only inhibited the SCP-
induced ambulatory activity, but protected the induction of 
the tolerance to SCP in a dose-dependent manner.  It has 
been demonstrated that repeated administrations of saline 
and comparatively lower doses of SCP, which were ineffec-
tive for significant increase in ambulatory activity, did not 
change the sensitivity to SCP (Kuribara and Tadokoro, 
Table 3.   Mean activity counts of mice following repeated administration of scopolamine (SCP: 2 mg/kg s.c.) 
+ post-SCP treatment with pilocarpine (PILO: 10 mg/kg s.c.) for 5 times at 3-day intervals.
Doses of drugs 1st 2nd 3rd 4th 5th
SCP→( 0 min)→PILO 21± 6 19± 5  20± 5 17± 6 19± 5
SCP→( 5m in)→PILO 34± 6 37±10  29± 7 33± 6 31± 6
SCP→(10 min)→PILO 76±10  63±11  51± 8 32± 6*  35± 7*
SCP→(20 min)→PILO 177±20 103±23* 68±12*  55± 8*  51± 6*
SCP→(30 min)→PILO 275±38 141±20* 96±11*  79± 9*  83±11*
SCP→(60 min)→PILO 427±62 209±31* 138±25* 110±18* 103±13*
SCP→(90 min)→PILO 529±69 199±27* 153±21* 106±15*  95±10*
N=10 in each group.  *: significantly higher (p<0.05) vs. the value of the 1st administration within group.
Table 4.   Mean activity counts after challenge-administration of scopolamine 
(SCP: 2mg/kg s.c.) and methamphetamine (MA: 2 mg/kg s.c.) to the mice 
received scopolamine SCP + post-SCP treatment with pilocarpine (PILO: 
10 mg/kg s.c.) at 0 (simultaneous), 5, 10, 20, 30, 60 and 90 min.
Pretreatments
Challenge-administrations
SCP MA
SCP + PILO (simultaneous) 694±98 1869±251
SCP→ ( 5 min)→PILO 505±79$ 1797±299
SCP→ (10 min)→PILO 181±55* 1902±351
SCP→ (20 min)→PILO 131±22* 1755±330
SCP→ (30 min)→PILO 119±25* 1830±362
SCP→ (60 min)→PILO 130±33* 1794±256
SCP→ (90 min)→PILO 98±24* 1949±375
SCP alone 101±25* 1908± 33
Saline 717±98 1751±328
N=5 in each group.  *: p<0.05 vs. the value of saline-pretreated group.   
$: p<0.05 vs. the value of SCP-pretreated group.
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1983, 1987).  Since PILO can antagonize with SCP at the 
central and peripheral muscarinic-cholinergic receptors, 
indicating that the pharmacological effect of SCP + PILO 
is equivalent to the low dose of SCP.  Furthermore, repeated 
administrations of PILO alone for 5 times at intervals of 
3 days may not induce significant change in the central or 
peripheral acetylcholine receptors.
The administration of PILO (10 mg/kg) at post-SCP 
period of 5 min partially protected the induction of toler-
ance to SCP.  PILO could not protect the SCP tolerance 
when it was given at post-SCP periods of 10 min and later. 
This result strongly suggests that the stimulation of central 
dopaminergic system caused by blockade of the central 
acetylcholine receptors at the early post-SCP period is 
essential factor for ambulation-increasing effect, and that 
the anti-cholinergic symptoms are important factors for 
induction of the tolerance to SCP.
Generally, repeated administrations of psychomotor 
stimulants to the mice induce significant sensitization to 
their ambulation-increasing effects through stimulation of 
the mesolimbic dopaminergic systems (Kalivas and Stewart, 
1991; Kuribara, 1995).  Repeated administrations of SCP + 
PILO did not change the sensitivity to MA.  This result is 
consistent with the previous report (Kuribara and Tadokoro, 
1987).  
The behavioral sensitization to psychomotor stimulants 
are considered to be intimately related to the reward 
effects, i.e., dependence liability (Piercem and Kumaresan 
2006; Berridge, 2007; Ikemoto, 2007) and psychotoxicity 
(Robinson and Becker, 1986; Tadokoro and Kuribara, 
1986; Pert et al., 1990).  The present and previous results 
support the evidence that severe dependence and abuse 
are rare for the muscarinic anti-cholinergic drugs (Sussam 
and Ames, 2001) and Angel’s trumpet (Greene et al., 
1996; Brunton et al., 2008), which contains muscarinic 
anti-cholinergic drugs such as SCP and atropine.  It is 
also considered from the present results that repeated use 
of anti-cholinergic drugs has low risk of increase in the 
psychotoxicity of psychomotor stimulants.
Conclusion
Pilocarpine (0: saline, 1, 3 and 10 mg/kg s.c.), a central- 
and peripheral-muscarinic acetylcholine receptor agonist, 
not only inhibited ambulation-increasing effect of scopol-
amine (2 mg/kg s.c.), but also the induction of tolerance 
to SCP.  The treatments with SCP + PILO or PILO alone 
produced no significant change in the sensitivity to MA 
(2 mg/kg s.c.).  It is concluded from the present results that 
the SCP-induced increase in ambulatory activity is resulted 
from the indirect stimulation of central dopaminergic systems 
through the blockade of central cholinergic receptors, and 
that the muscarinic anti-cholinergic symptoms are involved 
in the production of tolerance to SCP.  It is also considered 
that the psychotoxicity of psychomotor stimulants may not 
significantly increase following the use of anti-cholinergic 
drug alone.
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マウスの移所運動からみたムスカリン型コリン作動薬 pilocarpine による 
scopolamine耐性形成の阻止と覚せい剤感受性の修飾
栗原　久
東京福祉大学短期大学部（伊勢崎キャンパス）
〒372-0831 伊勢崎市山王町2020-1
抄録： 抗コリン薬 scopolamine（SCP: 2 mg/kg s.c.）のマウス移所運動促進効果は、コリン作動薬 pilocarpine （0：生理食塩水、
1, 3 10 mg/kg s.c.）の併用投与によって用量依存的に抑制された。SCPの反復投与による耐性形成は、PILO（10 mg/kg）の
同時または5分後投与で阻止されたが、10分以降の投与では阻止されなかった。PILOの単独投与はSCPに対する感受性
の変化を引き起こさず、また、SCP + PILOあるいはPILOのみの投与はmethamphetamine（2 mg/kg s.c.）に対する感受性
に変化を引き起こさなかった。これらの結果は、SCP投与直後（0-20分）における中枢および末梢の抗コリン作用の協同が
マウスの移所運動促進と耐性形成に重要であること、また抗コリン薬を単独使用した場合、覚せい剤のような精神運動刺激
薬の精神毒性に対する感受性亢進のリスクは低いことを示唆している。
（別刷請求先：栗原　久）
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